Does IPILIMUMAB Cause Hypertransaminasaemia? 73 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 73 reports of Hypertransaminasaemia have been filed in association with IPILIMUMAB (YERVOY). This represents 0.2% of all adverse event reports for IPILIMUMAB.
73
Reports of Hypertransaminasaemia with IPILIMUMAB
0.2%
of all IPILIMUMAB reports
8
Deaths
29
Hospitalizations
How Dangerous Is Hypertransaminasaemia From IPILIMUMAB?
Of the 73 reports, 8 (11.0%) resulted in death, 29 (39.7%) required hospitalization, and 4 (5.5%) were considered life-threatening.
Is Hypertransaminasaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IPILIMUMAB. However, 73 reports have been filed with the FAERS database.
What Other Side Effects Does IPILIMUMAB Cause?
Death (3,710)
Malignant neoplasm progression (3,296)
Diarrhoea (2,557)
Off label use (2,097)
Colitis (1,988)
Pyrexia (1,796)
Rash (1,556)
Fatigue (1,447)
Intentional product use issue (1,329)
Nausea (1,169)
What Other Drugs Cause Hypertransaminasaemia?
METHOTREXATE (436)
ACETAMINOPHEN (326)
PACLITAXEL (318)
CARBOPLATIN (304)
PEMBROLIZUMAB (231)
ATORVASTATIN (207)
CYCLOPHOSPHAMIDE (202)
PREDNISONE (198)
GEMCITABINE (196)
DEXAMETHASONE (169)
Which IPILIMUMAB Alternatives Have Lower Hypertransaminasaemia Risk?
IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE
IPILIMUMAB vs IPRATROPIUM
IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS
IPILIMUMAB vs IPTACOPAN
IPILIMUMAB vs IRBESARTAN